Selling a medical device manufacturer isn't a standard business sale. Your QMS, FDA registrations, and OEM contracts determine who can buy and how the deal must be structured. We run a confidential process built for regulated manufacturing.
Yes. A blind-profile, NDA-gated process lets qualified buyers evaluate the opportunity before your company name, customers, facility, or quality records are disclosed.
Regulatory continuity. Buyers need to understand QMS maturity, ISO 13485 status, FDA registration or listing implications, OEM contracts, validation records, and quality-team depth.
Quality records, CAPA history, contract assignment terms, customer/product revenue, financial normalization, key personnel retention, and facility or process documentation.
Regulated medical manufacturing seller intent. CNC, general manufacturing, healthcare-services, and valuation/multiple topics stay with their own owner pages.
Buyers evaluate more than revenue and equipment. They need proof that the earnings, customer relationships, operations, documentation, and team can transfer after a transaction.
Quality manuals, procedures, training records, audit history, and corrective-action discipline show whether the business can transfer cleanly.
Registration, listings, device history files, validation documentation, complaint history, and product exposure must match the company story.
Buyers review change-of-control, assignment, pricing, term, and customer-consent provisions before underwriting customer continuity.
IQ/OQ/PQ where applicable, device history records, lot traceability, and process validation all affect diligence confidence.
Revenue tied to one OEM, program, device, or product family needs context before buyers price the risk themselves.
Buyers want to see that quality, regulatory, production, and customer relationships do not depend on one owner or one employee.
Regulatory and quality items do not all transfer the same way. A good sale process identifies what continues with the entity, what requires buyer action, and what needs customer or regulatory planning before market launch.
| Item | Buyer diligence focus |
|---|---|
| FDA establishment registration | Whether it continues with the entity or requires updates after closing. |
| Device listings and product files | Ownership, completeness, and whether records support the represented revenue base. |
| ISO 13485 certificate | Scope, expiration, audit findings, open CAPAs, and transition requirements. |
| OEM supply agreements | Assignment clauses, customer consent, pricing, and program continuity. |
| Validation records | Process validation, traceability, and documentation quality. |

Value starts with normalized earnings, but buyers adjust their view based on transferability, risk, customer durability, operations, and the specific diligence issues in this niche. For a broader framework, see our manufacturing business valuation page.
Repeat work and program tenure help buyers understand durability.
Clean audits and well-managed CAPAs reduce diligence friction.
Current, supportable certifications can strengthen buyer confidence.
Concentration is manageable when program history and customer relationships are documented.
Records and files need to support the sale story.
Quality and operations depth reduce transition risk.
The cleanest sale processes start before buyer outreach. Preparation prevents buyers from discovering avoidable issues first and turning them into leverage.
A focused process protects confidentiality, qualifies buyers before disclosure, and positions the business around the factors buyers actually underwrite.
Confirm the quality and regulatory story before buyer outreach.
Tie earnings quality to customer, product, and QMS risk.
Target buyers qualified for regulated manufacturing.
Share sensitive files only after NDA and fit checks.
Prepare records before buyers can turn gaps into leverage.
For the broad owner pathway, see how we help owners sell a manufacturing business.
Broker selection should match the operating reality of the company. A generalist process can miss the details that specialized manufacturing buyers use to underwrite risk and value.
The Precision Firm runs a confidential, seller-first process for manufacturing owners. For broader advisor selection criteria, see our manufacturing business brokers page.
These pages stay in their own keyword lanes so each niche has a clear owner page.
For broader manufacturing M&A guidance on valuation, buyer diligence, and exit preparation, browse The Precision Firm's manufacturing M&A resources.
Yes. In a stock sale, FDA establishment registration and device listings generally continue under the same entity; in an asset sale, the buyer may need to re-register and update listings. A strong process addresses regulatory continuity before buyers reach diligence.
Most serious acquirers treat a current ISO 13485 certificate as a major credibility signal, and audit history matters as much as the certificate. Clean recent audits and well-documented CAPAs strengthen buyer confidence.
Typical buyers include larger contract manufacturers, private equity-backed manufacturing platforms, and strategic acquirers seeking validated capacity or OEM relationships. The right buyer depends on product mix, certifications, and contracts.
It depends on the assignment and change-of-control clauses. Many OEM supply agreements require consent, so contract transferability should be reviewed before market launch.
Buyers weigh recurring program revenue, quality system maturity, regulatory standing, customer concentration, and normalized earnings. Broad multiples are less useful without reviewing the company-specific risk profile.
No. The process should be blind-profile and NDA-gated, with employee and customer communication handled only at the stage you approve.
If you own this type of manufacturing business, start with a confidential conversation before buyer exposure creates leverage for the wrong side.
Nothing is marketed, listed, or shared without your approval.